SCHEMBL520237

SCHEMBL520237

c1cc(N2CCOCC2)ccc1Nc1ncc2ccc(C3CCCCC3)n2n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
INSR P06213 3/20 0.61
JAK2 O60674 4/20 0.56
CDK4 P11802 5/20 0.53
CDK1 P06493 4/20 0.53
CCNB1 P14635 4/20 0.53
CCND1 P24385 4/20 0.53
CCNE1 P24864 3/20 0.53
CDK2 P24941 3/20 0.53
AURKA O14965 2/20 0.52
CCNB2 O95067 2/20 0.48
CCND2 P30279 2/20 0.48
CCND3 P30281 2/20 0.48
CCNB3 Q8WWL7 2/20 0.48
CCNE2 O96020 1/20 0.48
CCNA2 P20248 1/20 0.48
CCNA1 P78396 1/20 0.48
ALK Q9UM73 2/20 0.48
IGF1R P08069 3/20 0.47
SYK P43405 2/20 0.47
ADORA3 P0DMS8 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL519703 0.88 ALK (0.62) INSRJAK2CDK4CDK1CCNB1
SCHEMBL521340 0.81 JAK2 (0.50) INSRJAK2CDK4CCND1CDK2
SCHEMBL519923 0.80 INSR (0.69) INSRJAK2CDK4AURKAALK
SCHEMBL16530360 0.80 JAK2 (0.49) INSRJAK2CDK4CDK1CCNB1
SCHEMBL521957 0.78 JAK2 (0.49) INSRJAK2CDK4CDK1CCNB1
SCHEMBL519464 0.77 INSR (0.65) INSRJAK2CDK4CCND3ALK
SCHEMBL520176 0.76 INSR (1.00) INSRJAK2ALKIGF1RJAK3
SCHEMBL519278 0.75 INSR (0.82) INSRJAK2ALKIGF1RSYK
SCHEMBL520274 0.74 INSR (0.60) INSRJAK2CDK4CDK1CCNB1
SCHEMBL519656 0.74 INSR (0.69) INSRJAK2ALKIGF1RSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP claimed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US claimed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US claimed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP claimed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO claimed
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 INSR 1738/4885JAK2 1/4885CDK4 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.